BIOGENERATION III SERVICES

The fund targets seed and Series A rounds, with a focus on preclinical through early-clinical-stage therapeutics, medical devices, and enabling technologies. The firm's sourcing prioritizes academic-spinout science from Benelux institutions such as the Netherlands Cancer Institute and KU Leuven, where the intellectual property is still unpartnered and the valuations remain disconnected from commercial expectations.

Prior to Fund III, the BioGeneration Ventures platform backed Dezima Pharma, a cholesterol drug developer that Amgen acquired in 2015 for up to $1.55 billion in milestone- and earnout-structured consideration (per Amgen, 2015). That exit demonstrated the platform's model of building single-asset companies to an inflection point and then selling to a major biopharmaceutical acquirer.

The firm sources primarily from academic and research-hospital spinout ecosystems in the Benelux region, particularly in the Netherlands and Belgium. Its proximity to institutions like the Netherlands Cancer Institute and the life sciences cluster around Leiden and Amsterdam gives it early access to unpartnered assets that are still pre-venture-syndicate.